


## STEM CELL MARKET ANALYSIS FACT SHEET

- **Stem Cell Company Revenues**
  - 2005: \$ 974,000
  - 2006: \$ 16,405,000
  - 2007: \$ 36,856,000 estimated
  - 2016: \$8.5 billion estimated (*new forecast to be released at Stem Cell Summit on Feb. 12*)
- **Largest Suppliers of Stem Cell Therapies** (Ranked in order of revenues generated from the sale of stem cell therapies or related products)
  - Blackstone Medical (a subsidiary of Orthofix Inc.)
  - Osiris Therapeutics
  - NuTech Medical
  - ViaCell
  - Aastrom Biosciences
  - Cytori
  - Geron
  - Stem Cell Inc.
  - BioE
- **Estimated Number of Companies Developing Stem Cell Products**  
200+ worldwide
- **Current Applications for Stem Cell Products**
  - Replacement for bone harvesting in spine fusion surgery
  - Bone growth and void fill in fresh fractures
  - Bone growth and void fill in non-union fractures
- **Stem Cell Products Expected to be Approved by the FDA in the Coming 36 Months**
  - Prochymal (treatment for graft vs. host disease)
  - Two (possibly three) treatments for damaged heart muscle due to heart disease
  - Chondrogen (repair of knee cartilage)
- **Market for Stem Cell Products**
  - Patient population in the United States for whom existing stem cell therapies are applicable: 2.5 million +

Year	Annual Sales est	Growth
2005	\$900	
2006	\$16,405	1722.8%
2007	\$36,856	124.7%
2008	\$146,085	296.4%
2009	\$303,496	107.8%
2010	\$707,332	133.1%
2011	\$1,331,515	88.2%
2012	\$2,335,116	75.4%
2013	\$3,422,513	46.6%
2014	\$4,741,545	38.5%
2015	\$6,346,551	33.8%
2016	\$8,476,845	33.6%



- Number of patients treated in 2006 the United States with stem cell products for orthopedic, cardiovascular, dental, aesthetic, oncologic or other indications: 5,900
- Market value of all public stem cell companies: \$1.655 billion
- The most common type of commercial stem cell: An adult stem cell derived from bone marrow
- **Other Facts:**
  - Each stem cell product is typically assayed by its supplier, and the number of viable stem cells is counted. A single dose of adult stem cells for therapeutic use usually has a minimum of  $10^4$  million viable stem cells.
  - The most common source of commercial stem cells in the United States is donor-derived adult stem cells.
  - Donor-derived adult stem cells are available as either minimally manipulated donated tissues or as cultured donor cells.
  - Stem cell therapies are likely to be disruptive treatments for the following medical sectors:

- Total knee implants
  - Stem cell therapies that repair worn articular or meniscus cartilage will delay and potentially reduce the need for total knee replacement surgery
- Sports medicine
  - Stem cell therapies will extend the continuum of care for “weekend warriors.” It is highly likely that stem cell therapies will become the standard of care for torn meniscus or damaged articular cartilage
- Heart muscle repair following heart attacks
- To improve flow of blood by stimulating growth of new capillaries and vessels to the heart muscle
- Use of bone marrow transplants
  - Stem cell therapies significantly reduce the effects of graft vs. host disease in patients with transplants.
- Treating the broad range of inflammation in the human body